NCIt definition : An orally bioavailable specific oral inhibitor of the pan-class I phosphatidylinositol
3-kinase (PI3K) family of lipid kinases with potential antineoplastic activity. Buparlisib
specifically inhibits class I PI3K in the PI3K/AKT kinase (or protein kinase B) signaling
pathway in an ATP-competitive manner, thereby inhibiting the production of the secondary
messenger phosphatidylinositol-3,4,5-trisphosphate and activation of the PI3K signaling
pathway. This may result in inhibition of tumor cell growth and survival in susceptible
tumor cell populations. Activation of the PI3K signaling pathway is frequently associated
with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance
to a variety of antineoplastic agents.;
UNII : 0ZM2Z182GD;
InChIKey : CWHUFRVAEUJCEF-UHFFFAOYSA-N;
CAS number : 944396-07-0;
Molecule name : BKM-120; AN-2025; BKM 120; AN 2025;